Actelsar HCT

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

Telmisartan, hydrochlorothiazide

Disponible depuis:

Actavis Group hf

Code ATC:

C09DA07

DCI (Dénomination commune internationale):

telmisartan, hydrochlorothiazide

Groupe thérapeutique:

Agents acting on the renin-angiotensin system, Angiotensin II antagonists and diuretics

Domaine thérapeutique:

Essential Hypertension

indications thérapeutiques:

Treatment of essential hypertension.Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

Descriptif du produit:

Revision: 17

Statut de autorisation:

Authorised

Date de l'autorisation:

2013-03-13

Notice patient

                                73
B. PACKAGE LEAFLET
74
PACKAGE LEAFLET: INFORMATION FOR THE USER
ACTELSAR HCT 40 MG/12.5 MG TABLETS
telmisartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Actelsar HCT is and what it is used for
2.
What you need to know before you take Actelsar HCT
3.
How to take Actelsar HCT
4.
Possible side effects
5.
How to store Actelsar HCT
6.
Contents of the pack and other information
1.
WHAT ACTELSAR HCT IS AND WHAT IT IS USED FOR
Actelsar HCT is a combination of two active substances, telmisartan
and hydrochlorothiazide in one
tablet. Both of these substances help to control high blood pressure.
-
Telmisartan belongs to a group of medicines called angiotensin II
receptor antagonists.
Angiotensin-II is a substance produced in your body which causes your
blood vessels to narrow
thus increasing your blood pressure. Telmisartan blocks the effect of
angiotensin II so that the
blood vessels relax, and your blood pressure is lowered.
-
Hydrochlorothiazide belongs to a group of medicines called thiazide
diuretics, which cause your
urine output to increase, leading to a lowering of your blood
pressure.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
ACTELSAR HCT IS USED TO
treat high blood pr
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Actelsar HCT 40 mg/12.5 mg tablets
Actelsar HCT 80 mg/12.5 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Actelsar HCT 40 mg/12.5 mg tablets
Each tablet contains 40 mg telmisartan and 12.5 mg
hydrochlorothiazide.
Actelsar HCT 80 mg/12.5 mg tablets
Each tablet contains 80 mg telmisartan and 12.5 mg
hydrochlorothiazide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Actelsar HCT 40 mg/12.5 mg tablets
White or almost white, 6.55 x 13.6 mm oval-shaped and biconvex tablets
marked with “TH” on one
side.
Actelsar HCT 80 mg/12.5 mg tablets
White or almost white, 9.0 x 17.0 mm capsule-shaped tablets marked
with “TH 12.5” on both sides.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
Actelsar HCT fixed dose combination (40 mg telmisartan/12.5 mg
hydrochlorothiazide and
80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults
whose blood pressure is not
adequately controlled on telmisartan alone.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
Actelsar HCT should be taken in patients whose blood pressure is not
adequately controlled by
telmisartan alone. Individual dose titration with each of the two
components is recommended before
changing to the fixed dose combination. When clinically appropriate,
direct change from monotherapy
to the fixed combination may be considered.
-
Actelsar HCT 40 mg/12.5 mg may be administered once daily in patients
whose blood pressure
is not adequately controlled by telmisartan 40 mg
-
Actelsar HCT 80 mg/12.5 mg may be administered once daily in patients
whose blood pressure
is not adequately controlled by telmisartan 80 mg
Actelsar HCT is also available at the dose strength 80 mg/25 mg
3
_Special populations: _
_Patients with renal impairment _
Periodic monitoring of renal function is advised (see section 4.4).
_Patients with hepatic impairment _
In patients with mild to moderate hepatic impairment the po
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 26-03-2013
Notice patient Notice patient espagnol 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 26-03-2013
Notice patient Notice patient tchèque 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 26-03-2013
Notice patient Notice patient danois 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation danois 26-03-2013
Notice patient Notice patient allemand 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 26-03-2013
Notice patient Notice patient estonien 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 26-03-2013
Notice patient Notice patient grec 24-10-2023
Notice patient Notice patient français 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation français 26-03-2013
Notice patient Notice patient italien 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation italien 26-03-2013
Notice patient Notice patient letton 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation letton 26-03-2013
Notice patient Notice patient lituanien 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation lituanien 26-03-2013
Notice patient Notice patient hongrois 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 26-03-2013
Notice patient Notice patient maltais 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 26-03-2013
Notice patient Notice patient néerlandais 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 26-03-2013
Notice patient Notice patient polonais 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 26-03-2013
Notice patient Notice patient portugais 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 26-03-2013
Notice patient Notice patient roumain 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 26-03-2013
Notice patient Notice patient slovaque 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 26-03-2013
Notice patient Notice patient slovène 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 26-03-2013
Notice patient Notice patient finnois 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 26-03-2013
Notice patient Notice patient suédois 24-10-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 26-03-2013
Notice patient Notice patient norvégien 24-10-2023
Notice patient Notice patient islandais 24-10-2023
Notice patient Notice patient croate 24-10-2023

Rechercher des alertes liées à ce produit

Afficher l'historique des documents